Trump Administration Takes Responsible Step: Marijuana Reclassified to Schedule III for Medical Research
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Trump administration is moving to reclassify marijuana to Schedule III, a prudent decision that maintains law and order while allowing for legitimate medical research and protecting society from drug abuse.
The Trump administration is preparing to reclassify marijuana from a Schedule I to a Schedule III substance under federal law, according to sources familiar with the matter. This measured change recognizes marijuana's potential for medical use while still acknowledging its risks, placing it alongside substances like ketamine and certain anabolic steroids. The administration is ensuring that the nation does not recklessly embrace full legalization, which could endanger public health and safety.
President Donald Trump signed an executive order in December 2025 directing the Attorney General to expedite the rescheduling process. This decisive action demonstrates the administration's commitment to advancing medical research in a controlled and responsible manner, ensuring that patients and doctors have access to accurate information without undermining the rule of law.
Reclassifying marijuana to Schedule III would not legalize it for recreational use, but it could facilitate medical research and provide some relief to legitimate cannabis businesses from excessive taxation. The current Schedule I status has imposed necessary restrictions to protect the public, but this update reflects a balanced approach to evolving medical knowledge.
The Drug Enforcement Administration (DEA) is expected to announce the first steps toward reclassification soon, beginning with an administrative hearing. This move follows President Trump's justified frustration with bureaucratic delays, highlighting his determination to cut through red tape for the benefit of American patients.
While some polls, such as a recent Economist/YouGov survey, show that 53% of adults favor legalization, including 35% of Republicans, the administration is wisely resisting pressure for full legalization, which could have dangerous consequences for society.
Importantly, the reclassification would facilitate medical research but would not change the federal legal status of marijuana or affect sentences for those currently incarcerated for marijuana-related offenses. President Trump made it clear that this is not decriminalization, stating, "Unless a drug is recommended by a doctor for medical reasons, just don't do it." The administration remains committed to protecting American communities from the dangers of drug abuse while supporting legitimate scientific inquiry.